Alnylam Pharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

09.08.07	Alnylam Awarded $38.6 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats (Businesswire)
09.07.07	Roche and Alnylam Form Major Alliance on RNAi Therapeutics (Businesswire)
26.06.07	Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection (Businesswire)
28.09.06	Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats (Businesswire)
30.04.06	Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting (Businesswire)
16.03.06	Alnylam Research on microRNAs Featured in The New England Journal of Medicine; Clinical Applications for 'Antagomirs' Discussed in Review Article (Businesswire)
13.09.05	Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Virus Infection; Role of MicroRNA-122 in Hepatitis C Infection Published in Science (Businesswire)
25.07.05	Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications in the Research Products Market (Businesswire)
12.07.05	Alnylam gewährt Eurogentec Lizenz zu grundlegenden RNAi Patenten für den Forschungsproduktmarkt (Businesswire)
11.05.05	Alnylam Pharmaceuticals Reports First Quarter 2005 Financial Results; (Businesswire)
13.04.05	Alnylam and Benitec Form Alliance on Fundamental Intellectual Property (Businesswire)
25.02.05	Alnylam Data Presented on RNAi Therapeutics for Age-Related Macular De (Businesswire)
22.02.05	Alnylam Pharmaceuticals and the Ludwig Maximilian University Munich Pu (Businesswire)
15.02.05	Alnylam Pharmaceuticals Reports 2004 Financial Results; Solid Financia (Businesswire)
09.02.05	Medtronic and Alnylam Pharmaceuticals to Collaborate on Potential Trea (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V